These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 23355099

  • 1. Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.
    Rutkowski P, Przybył J, Zdzienicki M.
    Mol Diagn Ther; 2013 Feb; 17(1):9-19. PubMed ID: 23355099
    [Abstract] [Full Text] [Related]

  • 2. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [Abstract] [Full Text] [Related]

  • 4. High-risk CD117-positive gastrointestinal stromal tumor of the colon in a 12-year-old girl: adjuvant treatment with imatinib mesylate.
    Okur A, Oguz A, Karadeniz C, Pinarli FG, Ozen O, Ekinci O.
    Tumori; 2012 Sep; 98(2):59e-62e. PubMed ID: 22678007
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumors: current management.
    Pisters PW, Patel SR.
    J Surg Oncol; 2010 Oct 01; 102(5):530-8. PubMed ID: 20063363
    [Abstract] [Full Text] [Related]

  • 6. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R, Kochar R.
    J Gastrointest Cancer; 2012 Dec 01; 43(4):547-52. PubMed ID: 22847491
    [Abstract] [Full Text] [Related]

  • 7. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
    Dretzke J, Round J, Connock M, Tubeuf S, Pennant M, Fry-Smith A, Hulme C, McCabe C, Meads C.
    Health Technol Assess; 2010 Oct 01; 14(Suppl. 2):63-70. PubMed ID: 21047493
    [Abstract] [Full Text] [Related]

  • 8. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S, Jia J, Pan YL, Tao DY, Lu HS.
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan 01; 42(1):42-3. PubMed ID: 23611272
    [No Abstract] [Full Text] [Related]

  • 9. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
    Cohen MH, Johnson JR, Justice R, Pazdur R.
    Oncologist; 2012 Jan 01; 17(7):992-7. PubMed ID: 22643537
    [Abstract] [Full Text] [Related]

  • 10. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
    López RL, del Muro XG.
    Anticancer Drugs; 2012 Jun 01; 23 Suppl():S3-6. PubMed ID: 22739667
    [Abstract] [Full Text] [Related]

  • 11. Imatinib treatment for gastrointestinal stromal tumour (GIST).
    Lopes LF, Bacchi CE.
    J Cell Mol Med; 2010 Jan 01; 14(1-2):42-50. PubMed ID: 19968734
    [Abstract] [Full Text] [Related]

  • 12. Multidisciplinary treatment of gastrointestinal stromal tumors.
    Kingham TP, DeMatteo RP.
    Surg Clin North Am; 2009 Feb 01; 89(1):217-33, x. PubMed ID: 19186237
    [Abstract] [Full Text] [Related]

  • 13. [GIST: adjuvant treatment in Austria].
    Brodowicz T, Kühr T.
    Wien Med Wochenschr; 2009 Feb 01; 159(15-16):399-402. PubMed ID: 19696984
    [Abstract] [Full Text] [Related]

  • 14. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H.
    Int J Clin Oncol; 2011 Dec 01; 16(6):741-5. PubMed ID: 21394667
    [Abstract] [Full Text] [Related]

  • 15. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
    Li J, Gong JF, Wu AW, Shen L.
    Eur J Surg Oncol; 2011 Apr 01; 37(4):319-24. PubMed ID: 21277730
    [Abstract] [Full Text] [Related]

  • 16. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul 01; 36(7):438-9. PubMed ID: 17845753
    [No Abstract] [Full Text] [Related]

  • 17. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ.
    Eur J Cancer; 2014 Jul 01; 50(10):1772-1778. PubMed ID: 24768330
    [Abstract] [Full Text] [Related]

  • 18. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
    Chang SC, Liao CH, Wang SY, Tsai CY, Chiang KC, Cheng CT, Yeh TS, Chen YY, Ma MC, Liu CT, Yeh CN.
    Medicine (Baltimore); 2015 Jun 01; 94(24):e1014. PubMed ID: 26091448
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG.
    BMC Gastroenterol; 2014 Jun 07; 14():105. PubMed ID: 24906683
    [Abstract] [Full Text] [Related]

  • 20. Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy.
    Annaberdyev S, Gibbons J, Hardacre JM.
    World J Surg Oncol; 2009 Mar 16; 7():30. PubMed ID: 19291285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.